We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
RNS Number : 2666D
Clinigen Group plc
09 October 2018
9 October 2018
Annual Report and Accounts, and notice of AGM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services company, announces that its Annual Report and Accounts for the year ended 30 June 2018 is now available on the Group's website at www.clinigengroup.com.
Copies of the Annual Report and Accounts will be posted to shareholders later today.
The Group will hold its Annual General Meeting ('AGM') on 8 November 2018 at 10.00am at Instinctif Partners' offices, 65 Gresham Street, London EC2V 7NQ. Shaun Chilton, Group Chief Executive Officer, will give a presentation at the AGM. The slides will be made available on the Group's website after the meeting. No new material information will be provided.
- Ends -
Contact Details
Clinigen Group plc Tel: +44 (0) 1283 495 010 Peter Allen, Chairman Matt Parrish, Head of Investor Relations Numis Securities Limited Tel: +44 (0) 20 7260 1000 Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653 4000 Marcus Jackson / Elliot Thomas Instinctif Partners Tel: +44 (0) 20 7457 2020 Melanie Toyne-Sewell / Alex Shaw / Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCFSMSAAFASEIS
(END) Dow Jones Newswires
October 09, 2018 02:00 ET (06:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions